NCT07486492 2026-03-20
Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer
The First Affiliated Hospital of Xiamen University
Phase EARLY_PHASE1 Not yet recruiting
Clinical Trials
97 trialsNCT07172282 2026-03-19
INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases
Northwell Health
Phase EARLY_PHASE1 Recruiting
NCT07193862 2026-02-27
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
Northwell Health
Phase EARLY_PHASE1 Recruiting
NCT05129787 2026-02-12
NEW-COMET
Oslo University Hospital
Phase NA Active not recruiting
NCT05665322 2026-01-23
MARGIN
Centre Hospitalier Universitaire de Nīmes
Phase NA Terminated
NCT05759728 2026-01-13
A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
Carina Biotech Limited
Phase 1/2 Recruiting
NCT04564898 2026-01-08
TriComB
Gruppo Oncologico del Nord-Ovest
Phase 1/2 Active not recruiting
NCT06332079 2026-01-05
HAITI
Gruppo Oncologico del Nord-Ovest
Phase 2 Terminated
NCT06540326 2025-12-22
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06353854 2025-10-06
CORESIM
Federation Francophone de Cancerologie Digestive
Recruiting
NCT06008119 2025-09-18
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Shanghai Kechow Pharma, Inc.
Phase 3 Recruiting
NCT04031872 2025-09-05
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
The Netherlands Cancer Institute
Phase 1/2 Withdrawn
NCT06764680 2025-08-24
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT05589597 2025-08-22
AUDREY
Enterome
Phase 1/2 Terminated
NCT04874207 2025-08-08
RePERSO
Rennes University Hospital
Phase 4 Completed
NCT07061210 2025-07-11
An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer
Fudan University
Phase 2 Not yet recruiting
NCT05248581 2025-07-08
Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases
University of Rochester
Recruiting
NCT07044921 2025-07-01
Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.
Chinese PLA General Hospital
Phase 2 Recruiting
NCT07012954 2025-06-24
ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC
Sun Yat-sen University
Phase 1/2 Recruiting
NCT07031570 2025-06-22
Efficacy and Safety of DEB-TACE Combined With HAIC Versus HAIC Alone in Patients With Unresectable CRLM
Peking University Cancer Hospital & Institute
Not yet recruiting
NCT04730544 2025-06-13
NIPISAFE
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Active not recruiting
NCT07007767 2025-06-06
Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT05727163 2025-05-30
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
Sun Yat-sen University
Phase 2 Recruiting
NCT06973343 2025-05-15
Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis
Anhui Provincial Cancer Hospital
Phase 2 Not yet recruiting
NCT06959589 2025-05-06
The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT04867525 2025-05-01
AZURITE
iOMEDICO AG
Active not recruiting
NCT03038568 2025-04-23
Assessing How Normal Variations in CT Scanning Affects Its Interpretation
Memorial Sloan Kettering Cancer Center
Active not recruiting
NCT05243862 2025-03-18
Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
Treos Bio Limited
Phase 2 Active not recruiting
NCT06282445 2025-02-17
Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 2 Recruiting
NCT04999306 2025-02-13
COLOFIGHT
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Terminated
NCT05513716 2025-01-01
COLOMET II
The Christie NHS Foundation Trust
Recruiting
NCT04940546 2024-12-03
Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients
Sun Yat-sen University
Phase 1/2 Active not recruiting
NCT06685276 2024-11-20
Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer
Chinese PLA General Hospital
Phase 2 Recruiting
NCT06682247 2024-11-12
A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer
Sun Yat-sen University
Not yet recruiting
NCT06679673 2024-11-07
SHR-1701 Combined with SHR2554 and BP102 for MCRC
Fudan University
Phase 2 Not yet recruiting
NCT03133273 2024-10-18
ONCOGRAM
University Hospital, Limoges
Phase NA Completed
NCT05584137 2024-10-15
Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC
Shanghai Henlius Biotech
Phase 2 Terminated
NCT03164655 2024-10-01
SULTAN
UNICANCER
Phase 2 Completed
NCT02286492 2024-09-05
Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer
Taiho Oncology, Inc.
Approved for marketing
NCT03488953 2024-07-31
LIVERT(W)OHEAL
Jena University Hospital
Phase NA Recruiting
NCT06447727 2024-06-07
Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM
Zhongda Hospital
Recruiting
NCT06440902 2024-06-04
Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA
Fudan University
Phase 2 Recruiting
NCT06379399 2024-04-23
Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC
Zhejiang Cancer Hospital
Phase 1/2 Recruiting
NCT01910610 2024-03-12
STRATEGIC-1
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 3 Unknown
NCT03439462 2024-01-02
Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer
Aadi Bioscience, Inc.
Phase 1/2 Completed
NCT05092880 2023-12-19
CAIRO7
UMC Utrecht
Phase 2 Recruiting
NCT04751955 2023-10-31
A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)
Korean Cancer Study Group
Phase 1/2 Withdrawn
NCT04721301 2023-10-17
Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial
University Hospital Heidelberg
Phase 1 Completed
NCT06027775 2023-09-07
Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases
Fudan University
Completed
NCT04262687 2023-08-18
POCHI
Federation Francophone de Cancerologie Digestive
Phase 2 Unknown